Skip to main content
CADL logo

CADL · Candel Therapeutics, Inc. · Documents

Track CADL — free
$5.16 -0.16 (-3.04%)
Market Cap
$402.43M
Shares
78.45M
Volume · Nov 19 1.16M Avg daily vol (3M) 1.26M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $38.18M 10-K filed Mar 12, 2026 Quarterly report New FY2026 Q3 10-Q filed Nov 12, 2026 Latest results New Aglatimagene BLA submission planned for middle 2027 8-K filed Nov 12, 2026
2026
Nov 18
Investor event
BLA completion delayed to mid-2027 by six-month assay validation

Candel's CEO said the company learned on November the 9th that validating the IU assay would take six months, pushing BLA completion to mid-2027. The delay is analytical rather than manufacturing-related, and the CV must consistently stay below 30%. The launch target moves from Q4, 2027 to Q1, 2028.

9 source passages
And then it came to my attention, actually, I know exactly when, November the 9th at 9.30 So that takes six months. I know exactly when, November the 9th at 9.30 is mid-2027, is that the expected timing for the complete BLA submission? This has nothing to do with manufacturing. and the CV needs to be consistently lower than 30%. We have successfully developed it, the IU assay. we were aiming for launch in Q4, 2027. So now we aim for launch in Q1, 2028 Open the document at this passage
Nov 18
Investor event
Potency assay validation delays BLA filing by six months

Candel Therapeutics said it became aware on November the 9th that validation of its potency assay would take six months. The company said the delay is analytical rather than manufacturing-related, and the coefficient of variability must be consistently lower than 30%. Launch is now targeted for Q1, 2028, and the cash runway extends into the second quarter of 2028.

7 source passages
Candel Therapeutics develops viral immunotherapies we became aware of this on November the 9th it will take six months This has nothing to do with manufacturing the CV needs to be consistently lower than 30% we aim for launch in Q1, 2028 the expected cash runway into the second quarter of 2028 Open the document at this passage
Nov 12
Current report 8-K
New $50,000,000 common stock ATM offering

On November 12, 2026, Candel Therapeutics, Inc. entered a new at-the-market agreement with Jefferies LLC for up to $50,000,000 of common stock, after selling approximately $50,000,000 under its 2025 agreement. Jefferies receives a 3.0% commission on gross proceeds.

Other events Read from the first part of this long document
3 source passages
On November 12, 2026, Candel Therapeutics, Inc. (the “Company”) entered into a Second Amended and Restated Open Market Sale Agreement^SM^ (the “2026 Sales Agreement”), with Jefferies LLC (“Jefferies”), to sell shares of the Company’s common stock, par value $0.01 per share (“Common Stock”), from time to time through Jefferies acting as sales agent, having an aggregate offering price of up to $50,000,000 (such amount to be in addition to the aggregate gross sales proceeds received by the Company from the sale of Common Stock prior to the date hereof pursuant to the 2025 Sale Agreement (as defined below)) (the “ATM Shares”). As of November 12, 2026, the Company had sold an aggregate of approximately $50,000,000 of ATM Shares under the 2025 Sale Agreement. The 2026 Sales Agreement provides that Jefferies will be entitled to a fixed commission rate of 3.0% of the gross proceeds of the ATM Shares sold under the 2026 Sales Agreement. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Aglatimagene improved prostate survival; pancreatic program paused

Candel Therapeutics said aglatimagene achieved a 39% improvement in prostate cancer-specific disease-free survival at 58.0 months median follow-up, plans a BLA submission in the middle of 2027, and paused pancreatic cancer development.

Read from the MD&A section
4 source passages
In December 2020, we formally changed our name from Advantagene to Candel Therapeutics, Inc. Among the 745 patients enrolled in the randomized, double-blind, placebo-controlled trial, the aglatimagene arm exhibited a 39% improvement in prostate cancer-specific disease-free survival (PCa-specific DFS) compared to placebo after a median follow-up of 58.0 months. Due to timelines associated with certain assay refinement, we currently plan to submit this BLA in the middle of 2027 pending the result of that dialogue. In October 2025, we decided to pause on further clinical development of aglatimagene in PDAC, in the context of portfolio prioritization, unless externally funded through a grant or other non-dilutive external funding. Open the document at this passage
Nov 12
Current report 8-K
Aglatimagene BLA submission planned for middle 2027

Candel Therapeutics plans to submit aglatimagene’s prostate cancer BLA in the middle of 2027 pending FDA dialogue, while $203.1 million in cash is expected to fund operations into Q2 2028. Third-quarter 2026 net loss widened to $21.9 million from $11.3 million.

Financial results
3 source passages
The Company is in ongoing dialogue with the FDA regarding the submission of a Biologics License Application (BLA) for aglatimagene in prostate cancer. Due to timelines associated with certain assay refinement, the Company currently plans to submit this BLA in the middle of 2027 pending the result of that dialogue. Cash and cash equivalents of $203.1 million, as of September 30, 2026, are expected to be sufficient to fund the Company’s current operating plan into Q2 2028. Net Loss: Net loss for the third quarter of 2026 was $21.9 million compared to net loss of $11.3 million for the third quarter of 2025 and included net other income of $1.1 million and $1.9 million, respectively. Open the document at this passage
Nov 10
Investor event
Aglatimogene Prostate Trial Met Primary Endpoint

CADL’s aglatimogene prostate trial achieved its primary endpoint in December 2024; payer research indicates a median price range of $285,000 for three administrations, though the company said that price was not assured.

6 source passages
# Conference Transcript - CADL 2026-11-10 So first, we have achieved our primary endpoint in December 2024, which was the CH3 survival, supported by secondary endpoints like patients achieving a PSA nadir of less than 0.2 nanogram per mil. The median price range is $285,000. In our case, that would be for three administrations. I don't say that we get this price. We are doing the additional payer research. Open the document at this passage
Nov 10
Investor event
Phase 3 programs advance in prostate and lung cancer

Candel Therapeutics said aglatimogene met its phase 3 primary endpoint in localized prostate cancer in December 2024, with no increase in serious adverse events versus placebo. A phase 3 study in second-line non-small cell lung cancer has begun.

3 source passages
So, we have achieved our primary endpoint in December 2024, which was the CH3 survival, supported by secondary endpoints like patients achieving a PSA nadir of less than 0.2 nanogram per mil. We have not shown any increase in serious adverse events after aglatimidine versus placebo, so it's always about benefit-risk that payers focus on. So, you have a phase three registrational effort that you just started a few months ago. This is in. Second-line non-small cell lung cancer, you are trying to defeat that which has not been defeated by the drug development industry to date, which is docetaxel as a second-line comparator. Open the document at this passage
Apr 29
Proxy statement DEF 14A Meeting Jun 23, 2026
Proxy statement AI summary on its way
Mar 12
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $38.18M Diluted EPS -$0.72
2025
Showing 1–50 of 136 documents
Key facts CIK 1841387 CUSIP 137404109 13F (30d) 151 filings 137 filers Visit website Investor relations